Intranasal oxytocin in the treatment of schizophrenia
Phase 2
- Conditions
- Schizophrenia
- Registration Number
- JPRN-UMIN000014650
- Lead Sponsor
- the ethics committee of the National Center of Neurology and Psychiatry
- Brief Summary
Oxytocin significantly reduced scores on the positive and negative syndrome scale, especially on the negative symptoms. As for cognition, there was an improvement of the verbal fluency. Furthermore, the change of the negative score in positive and negative syndrome scale showed a negative correlation with the gray matter volumes of the right insula and left cingulate cortex.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Participants were excluded if they had a prior medical history of central nervous system disease or severe head injury, pregnancy or the possibility of pregnancy, or if they met the criteria for substance abuse or dependence.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of clinical symptoms calculated by the PANSS.
- Secondary Outcome Measures
Name Time Method The change of social cognition and the body weight.